GENUS (GNS) – Pharmaceuticals
| Price: £25.27 +6.4% | P/E: 39.8x |
| Market Cap: £1.59bn | Yield: 1.38% |
Animal genetics firm Genus has released a short trading update ahead of its AGM saying trading for the four months to the end of October has been better than expected.
Therefore, it now sees pre-tax profit for the year to June 2026 ‘modestly ahead’ of the midpoint of current market expectations.
The current range of estimates as compiled by the company is from £77.6 million to £85 million, although that excludes any benefit from the Chinese porcine vaccine joint venture which was announced in early September.
Our view
Genus shares have rallied more than 50% since the start of the year thanks to a string of positive updates, leaving them fairly valued at 27x on our CAPE model.
However, today’s strong reaction today suggests there is more momentum so the stock could keep running.
Read the press release here: https://www.genusplc.com/investors/
Disclaimer: This content is for information only and is not investment advice. Always do your own research before investing. Click here to see full disclaimer.
